{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zoladex&page=2", "query": { "intervention": "Zoladex", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zoladex&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T04:06:45.225Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01492972", "title": "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Androgen Suppression Therapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Proton Collaborative Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 192, "start_date": "2012-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Warrenville", "state": "Illinois" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Hampton", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492972" }, { "nct_id": "NCT03279250", "title": "Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage IIB Prostate Cancer AJCC v8", "Stage IIC Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Gonadotropin-releasing Hormone Analog", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 86, "start_date": "2017-10-13", "completion_date": "2021-05-11", "has_results": true, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03279250" }, { "nct_id": "NCT05050084", "title": "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Buserelin", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2050, "start_date": "2021-12-06", "completion_date": "2031-11-11", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 567, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050084" }, { "nct_id": "NCT00283803", "title": "Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Exisulind", "type": "DRUG" }, { "name": "luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Antiandrogen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2002-03-12", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283803" }, { "nct_id": "NCT00586898", "title": "Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate", "Cancer", "Hormonal Cycling" ], "interventions": [ { "name": "GnRH", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Testosterone transdermal gel", "type": "DRUG" }, { "name": "Estrogen transdermal patch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2001-07", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2016-03-25", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586898" }, { "nct_id": "NCT02941926", "title": "Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3246, "start_date": "2016-11-30", "completion_date": "2022-11-09", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 71, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02941926" }, { "nct_id": "NCT03867357", "title": "Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Prostate Cancer", "Androgen Deprivation Therapy" ], "interventions": [ { "name": "GnRH agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Institute for Biomedical and Clinical Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 60, "start_date": "2018-12-07", "completion_date": "2023-09-01", "has_results": false, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867357" }, { "nct_id": "NCT02586675", "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Cancer - Female", "Breast Cancer - Male" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-02-23", "completion_date": "2021-10-27", "has_results": true, "last_update_posted_date": "2022-01-21", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586675" }, { "nct_id": "NCT00220194", "title": "A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cancer of Prostate" ], "interventions": [ { "name": "leuprolide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "San Bernardino Urological Associates Medical Group Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2003-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-14", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 1, "location_summary": "San Bernardino, California", "locations": [ { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220194" }, { "nct_id": "NCT01717053", "title": "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Androgen deprivation", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 37, "start_date": "2014-01-17", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-09-24T04:06:45.225Z", "location_count": 3, "location_summary": "Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01717053" } ] }